<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00187057</url>
  </required_header>
  <id_info>
    <org_study_id>AT-1</org_study_id>
    <nct_id>NCT00187057</nct_id>
  </id_info>
  <brief_title>Study for Treatment of Cancer in Children With Ataxia-telangiectasia</brief_title>
  <official_title>Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot/feasibility study designed to investigate the feasibility of treating
      children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as
      non-A-T patients with cancer would receive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 10-30% of A-T patients will develop a malignancy during their lifetime. The
      vast majority of these cancers are of lymphoid origin. There is no consensus regarding the
      optimal strategy for treating children with A-T who develop hematopoietic malignancies.
      Historically, many of these children have been treated with therapy that is much less
      intensive than the conventional approach for non-A-T patients with similar malignancies
      during the corresponding treatment era. Although these less intensive approaches may have
      stemmed from perceptions that these children would not tolerate intensive therapy, there is
      in fact no data to suggest that these children cannot tolerate intensive therapy. However, it
      is clear that children with A-T require a modification in certain components of intensive
      therapy.

      To provide children with A-T and either ALL or malignant lymphoma the best chance for a cure,
      we propose to use modern therapeutic strategies with minimal modifications which address the
      unique toxicity profile encountered in treating children with A-T.

      Secondary objectives include:

        -  To clinically and biologically characterize the malignancies occurring in children with
           A-T (usually malignant lymphoma or ALL). This will include in vitro drug sensitivity
           screening.

        -  To study chemotherapy-induced DNA damage in children with A-T.

      Detailed Description of Treatment Plan:

        -  Acute Lymphoblastic Leukemia (ALL) Low Risk:

      Induction:

      Prednisone 40 mg/m2/day PO days 1-28

      Vinblastine 6 mg/m2/dose IV day 8

      Vincristine 1.5 mg/m2/dose days 1, 15

      Daunomycin 20 mg/m2/week IV days 1,15

      Asparaginase 10,000 U/m2/dose IM days 2, 4, 6, 8, 10, 12

      VP-16 225 mg/m2/dose Days 22, 25, 29

      Ara-C 300 mg/m2/dose Days 22, 25, 29

      All patients will receive CNS therapy with triple intrathecal therapy on days 1, 22 and 43 of
      induction treatment, dose age adjusted.

      Consolidation:

      Methotrexate 2 mg/m2 IV day 43 and 50 and mercaptopurine 75 mg/m2 days 43-56.

      Continuation therapy (120 weeks):

      Week:

        1. 6-MP + MTX

        2. 6-MP + MTX

        3. 6-MP + MTX

        4. Dex + VCR

        5. 6-MP + MTX

        6. 6-MP + MTX

        7. 6-MP + HDMTX

        8. Dex + VCR

        9. 6-MP + MTX

       10. 6-MP + MTX

       11. 6-MP + MTX

       12. Dex + VCR

       13. 6-MP + MTX

       14. 6-MP + MTX

       15. 6-MP + HDMTX

      This sequence will be repeated through week 52 after which 6-MP + MTX will be given weekly to
      complete 120 weeks. IT MHA (MTX, hydrocortisone, Ara-C) on weeks 1, 2, 7, and 15 and then
      every 4-8 weeks depending on CNS status.

      Dosages, Schedules and Routes:

      6-MP 75 mg/m2 PO; daily x 7

      MTX 40 mg/m2 IM or IV; q (every) week;

      Dex 6 mg/m2 PO; in 3 divided doses daily x 7

      VCR 1.5 mg/m2 IV (max. 2.0 mg)

      HDMTX 2 g/m2 IV over 2 hours, every 8 weeks

      Reinduction:

      Reinduction therapy (weeks 16-21). Reinduction therapy (same as initial induction treatment
      minus dose 2 and 3 of VP16 +ara-C and minus day 22 intrathecal therapy) will be given after
      bone marrow examination on week 15 confirms complete remission.

        -  Acute Lymphoblastic Leukemia (ALL) - High Risk

      Induction:

      Prednisone 40 mg/m2/day PO) divided in 3 doses days 1-28

      Vinblastine 6 mg/m2/dose IV day 8

      Vincristine 1.5 mg/m2/dose days 1, 15

      Daunomycin 20 mg/m2/week IV days 1, 15

      Asparaginase 10,000 U/m2/dose IM days 2, 4, 6, 8, 10, 12, (15, 17, 19)

      VP16 225 mg/m2/dose days 22, 25, 29

      Ara-C 300 mg/m2/dose days 22,25,29

      All patients will receive triple IT therapy on days 1, 22 and 43 of induction with additional
      IT therapy on days 8 and 15 if CNS leukemia (CNS 2 or CNS 3) is present at diagnosis. If
      required, for patients with CNS 2 and 3 at diagnosis, IT therapy will continue until 2
      consecutive CSF studies are normal (i.e., days 29 and 36).

      Consolidation:

      HDMTX 2 mg/m2 IV day 43 and 50

      6 MP 75 mg/m2 PO days 43-56

      Continuation Therapy (120 weeks):

      Week:

        1. Dex + VCR

        2. VP-16 + CTX

        3. 6-MP + MTX

        4. MTX + Ara-C

        5. Dex + VCR

        6. VP-16 + CTX

        7. 6-MP + HDMTX

        8. 6-MP + MTX

        9. Dex + VCR

       10. VP-16 + CTX

       11. 6-MP + MTX

       12. MTX + Ara-C

       13. Dex + VCR

       14. VP-16 + CTX

       15. 6-MP + HDMTX

      These sequences will be repeated through week 52, after which 6MP/MTX will be given weekly to
      complete 120 weeks.

      IT MHA (MTX, hydrocortisone, Ara-C) on weeks 1, 2, 7, and 15 and then every 4-8 weeks
      depending on CNS status and risk status.

      Dosages, Schedules and Routes:

      VP 16 225 mg/m2 IV once a week

      Cyclophosphamide 300 mg/m2 IV (with MESNA) once a week in addition to the 6 hour IV hydration

      6-MP 75 mg/m2 PO; daily x 7

      MTX 40 mg/m2 IM or IV once a week

      Ara-C 300 mg/m2 IV push; once a week

      Dex 8 mg/m2/day PO; in 3 divided doses daily x 7

      VCR 1.5 mg/m2 IV push (max. 2.0 mg)

      HDMTX 2 g/m2 IV over 2 hours; every 8 weeks x 7

        -  B-Cell Non-Hodgkins Lymphoma

      Overview - the chemotherapy regimen used varies with grouping based on extent of disease

      Group A

      Induction (COPAD x 2 cycles):

      Cyclophosphamide 500 mg/m2/day (divided every 12 hour) IV (with MESNA) Day 1, 2, 3

      Vincristine 2.0 mg/m2 IV Day 1

      Vinblastine 6 mg/m2 IV Day 6

      Prednisone 60 mg/m2/day (bid) PO Day 1-5

      Adriamycin 50 mg/m2 (over 6 hrs) IV Day 1

      G-CSF 5 mcg/kg/day until count recovery.

      Group B

      COP Induction:

      Cyclophosphamide 300 mg/m2 IV (divided every 12 hours) IV (with MESNA) Day 1

      Vincristine 1.0 mg/m2 IV Day 1

      Prednisone 60 mg/m2/day (divided bid) PO days 1-7

      CNS Therapy Intrathecal Day 1 - dose age adjusted

      COPAD-M3 Induction x 2 cycles:

      Vinblastine 6 mg/m2 IV Day 1

      HD MTX 3 mg/m2 IV over 3 hours Day 1 with leucovorin rescue

      CNS Therapy intrathecal each age adjusted Day 2, 6

      Cyclophosphamide 500 mg/m2/day (second course 1 mg/m2/day) IV (with MESNA) Day 2, 3, 4

      Adriamycin 50 mg/m2 IV Day 2

      Prednisone 60 mg/m2 (divided bid) PO Day 1-5

      G-CSF 5 mcg/kg/day until count recovery

      CYM Consolidation x 2 cycles:

      HD MTX 3 mg/m2 IV over 3 hours Day 1 with leucovorin rescue

      Ara-C 100 mg/m2/day CI/IV (x 5 days) Day 2-6

      CNS Therapy intrathecal each age adjusted Day 2 and 7

      Maintenance:

      Prednisone 60 mg/m2/day (divided bid) PO Day 1-5

      HDMTX 3 mg/m2 IV over 3 hours Day 1 with leucovorin rescue

      CNS Therapy intrathecal each age adjusted Day 2

      Cyclophosphamide 500 mg/m2/day IV (with MESNA) Day 2, 3

      Adriamycin 50 mg/m2 IV Day 3

      Vincristine 2 mg/m2 IV Day 1

      G-CSF 5 mcg/kg/day until count recovery

        -  Limited Stage Non-Hodgkins Lymphoma

      Induction:

      Vincristine 2 mg/m2 IV days 1, 22 (maximum dose 2 mg)

      Vinblastine 6 mg/m2 IV, day 8

      Prednisone 40 mg/m2/day in 3 divided doses x 28 days

      Adriamycin 30 mg/m2/day IV over one hour days 1 and 22

      Cyclophosphamide 750 mg/m2/day IV days 1 and 22

      Triple IT chemotherapy for participants with head and neck primary tumors on days 1, 8, 22.
      Each dose age adjusted.

      Consolidation - start day 43:

      Adriamycin 30 mg/m2 by IV

      Cyclophosphamide 750 mg/m2

      Prednisone 40 mg/m2 in 3 divided doses x 5 days

      Vincristine 2.0 mg/m2 (max. 2.0 mg) by IV

      Triple IT chemotherapy for head and neck primaries on days 43 and 64.

      Maintenance:

      Maintenance chemotherapy will be administered only to patients with lymphoblastic lymphoma
      and will consist of 24 weeks of chemotherapy with oral daily 6-MP and weekly oral
      methotrexate (and TIT every 6 weeks for patients with head and neck primaries) after
      induction/consolidation.

        -  Hodgkins Disease

      Participants with favorable disease will receive VAMP chemotherapy:

      VAMP chemotherapy doses and schedule:

      Vinblastine 6 mg/m2, IV day 1, 15 (maximum dosage: 10 mg)

      Adriamycin 25 mg/m2, IV day 1, 15

      Methotrexate 20 mg/m2, IV day 1, 15

      Prednisone 40 mg/m2 PO day 1-14 divided into 3 daily doses

      Repeat cycle every 28 days, total number of cycles = 6 (NO RADIATION THERAPY)

      Participants with unfavorable disease will receive VAMP and COP:

      VAMP chemotherapy doses (cycles 1, 3, 5, 7)

      Vinblastine 6 mg/m2 IV day 1, 15

      Adriamycin 25 mg/m2 IV day 1,15

      Methotrexate 20 mg/m2 IV day 1, 15

      Prednisone 40 mg/m2 (divided into 3 daily doses) PO day 1-14

      COP chemotherapy doses (cycles 2, 4, 6, 8)

      Cyclophosphamide 600 mg/m2 IV (with MESNA) day 1, 8

      Vincristine 1.4 mg/m2 IV day 1,8 (max dose 2 mg)

      Procarbazine 100 mg/m2 PO day 1-14

      (NO RADIATION THERAPY)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the feasibility of delivering modified intensive chemotherapy to children with A-T who present with cancer.</measure>
    <time_frame>The completion of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ataxia-Telangiectasia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acute Lymphoblastic Leukemia (ALL) Low Risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acute Lymphoblastic Leukemia (ALL) - High Risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>B-Cell Non-Hodgkins Lymphoma (Group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>B-Cell Non-Hodgkins Lymphoma (Group B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hodgkins Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine, vincristine, prednisone, daunorubicin</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, methotrexate, cyclophosphamide, L-asparaginase</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide, cytarabine, mercaptopurine</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone, procarbazine</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy, intrathecal chemotherapy, steroid therapy</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have a diagnosis of Ataxia-Telangiectasia (A-T).

          -  Patient must have a diagnosis of either acute lymphoblastic leukemia (ALL) or lymphoma
             (non-Hodgkin lymphoma or Hodgkin's disease).

          -  Patients with other malignancies (solid tumors, rare malignancies, or relapsed
             hematopoietic malignancies) will be eligible for the biologic studies of this
             protocol; they will receive best clinical management chemotherapy.

          -  Patients do not have to be previously untreated. If prior chemotherapy has already
             started (up through induction), therapy will be continued according to protocol at a
             clinically appropriate time point.

        Exclusion Criteria:

          -  Patients who do not have a diagnosis of Ataxia Telangiectasia (A-T).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John T. Sandlund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <reference>
    <citation>Sandlund JT, Kastan MB, Kennedy W, Behm F, Entrekin E, Pui CH, Kalwinsky DT, Raimondi SC. A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia. Cancer Genet Cytogenet. 2006 Jul 1;168(1):69-72.</citation>
    <PMID>16772123</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ataxia</keyword>
  <keyword>alphafetoprotein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Ataxia Telangiectasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

